Sponsor pipeline

Mirati Therapeutics Inc. clinical trial pipeline

Get alerts when Mirati Therapeutics Inc.'s trials change

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

Notable

SAPPHIRE · Sitravatinib Plus Nivolumab vs Docetaxel · Advanced Non-Squamous Non-Small Cell Lung Cancer

Reclassified as terminated (was completed)

Mirati Therapeutics Inc.Phase 3 NCT03906071 Registry history of NCT03906071 on ClinicalTrials.gov (opens the registry)

Sep 30, 2026

Show 2 trials with minor changes only

Minor

Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

Trial completed

Mirati Therapeutics Inc.Phase 1 NCT07723118 Registry history of NCT07723118 on ClinicalTrials.gov (opens the registry)

Sep 28, 2026
Minor

MRTX849 With Cetuximab vs Chemotherapy · Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Study completion pushed from Jul 31, 2026 to Oct 23, 2026

Mirati Therapeutics Inc.Phase 3 NCT04793958 Registry history of NCT04793958 on ClinicalTrials.gov (opens the registry)

Sep 28, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1/2		1
Phase 2		3
Phase 2/3		1
Phase 3		3

Disease areas by active trials

Lung Cancer (5) · Non-Small Cell Lung Cancer (NSCLC) (5) · Colorectal Cancer (2) · Pancreatic Cancer (1)

Get alerts when Mirati Therapeutics Inc.'s trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.

Start monitoring free